Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Preoperative ERCP & Increased Pancreatic Cancer Mortality

Clin Gastroenterol Hepatol; ePub 2018 Dec 7; Rustgi, et al

Patients with pancreatic cancer who underwent preoperative endoscopic retrograde cholangiopancreatography (ERCP) did not have an increased risk of death compared with those who proceeded directory to surgery, a new study found. Researchers used Surveillance, Epidemiology and End Results (SEER) and linked Medicare claims data to identify patients aged >65 years with cancer localized to the head of the pancreas from 2000 through 2011. They found:

  • Among 16,670 patients with cancer of the head of the pancreas, 2,890 (17.3%) underwent surgical resection; 1,864 (64.5) received preoperative ERCP.
  • Patients who received preoperative ERCP did not have increased risk of death vs patients who underwent resection alone (HR, 1.02), after adjustment for confounders.


Rustgi SD, Amin S, Yang A, et al. Preoperative endoscopic retrograde cholangiopancreatography is not associated with increased pancreatic cancer mortality. [Published online ahead of print December 7, 2018]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2018.11.056.